GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Debt-to-Equity

SER (Serina Therapeutics) Debt-to-Equity : -2.57 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Debt-to-Equity?

Serina Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $9.98 Mil. Serina Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.11 Mil. Serina Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-4.31 Mil. Serina Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was -2.57.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Serina Therapeutics's Debt-to-Equity or its related term are showing as below:

SER' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.57   Med: -0.14   Max: -0.01
Current: -2.57

During the past 2 years, the highest Debt-to-Equity Ratio of Serina Therapeutics was -0.01. The lowest was -2.57. And the median was -0.14.

SER's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs SER: -2.57

Serina Therapeutics Debt-to-Equity Historical Data

The historical data trend for Serina Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics Debt-to-Equity Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22
Debt-to-Equity
-0.01 -0.05

Serina Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Mar24
Debt-to-Equity -0.01 N/A -0.05 -0.23 -2.57

Competitive Comparison of Serina Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Serina Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Serina Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's Debt-to-Equity falls into.



Serina Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Serina Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Serina Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Serina Therapeutics  (AMEX:SER) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Serina Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Serina Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
Address
601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.